IQVIA Lifts 2025 Outlook Amid Mixed Q1 Results

IQVIA Holdings reported first-quarter 2025 adjusted earnings per share of $2.70 and revenue of $3.83 billion, a 2.5% year-over-year increase, surpassing analyst forecasts. Net income declined to $249 million from $288 million, impacted by higher stock-based compensation and losses in unconsolidated affiliates. The Technology & Analytics Solutions segment led growth with a 6.4% revenue rise, while Research & Development Solutions saw only marginal gains amid industry uncertainty. Management raised its 2025 revenue outlook to $16–$16.4 billion, supported by a weaker dollar and a growing backlog from demand for clinical research services, while maintaining its adjusted profit forecast. Despite strong results, IQVIA’s stock has dropped over 20% year-to-date, underperforming the broader market. Investors remain focused on earnings estimate revisions and management's guidance due to ongoing macroeconomic and industry headwinds.